Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy

The Journal of Headache and Pain

Research Article

M Avenali¹  I De Paoli¹  M Berlangieri¹  R De Icco¹  G Nappi²  G Sances²  M Allena²  E Berra²  E Guaschino²  S Cristina²  N Ghiotto²  C Tassorelli³  G Sandrini³  M Bolla⁴ 

[1] Department of Brain and Behavior, University of Pavia, Pavia, Italy;Headache Science Centre, “C. Mondino” National Neurological Institute, Pavia, Italy;Headache Science Centre, “C. Mondino” National Neurological Institute, Pavia, Italy;Department of Brain and Behavior, University of Pavia, Pavia, Italy;Neurological and Orthopedic Rehabilitation Unit, Clinica “Villa Esperia”, SaliceTerme, Italy;

关键词: Migraine;    Chronic migraine;    Episodic migraine;    Cost;    Resource utilization;    Italy;   

DOI  :  10.1186/s10194-015-0532-6

 received in 2015-02-25, accepted in 2015-05-12,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundChronic migraine (CM) has a high impact on functional performance and quality of life (QoL). CM also has a relevant burden on the National Health Service (NHS), however precise figures are lacking. In this pilot study we compared the impact in terms of costs of CM and episodic migraine (EM) on the individual and on the National Health System (NHS). Furthermore, we comparatively evaluated the impact of CM and EM on functional capability and on QoL of sufferers.MethodsWe enrolled 92 consecutive patients attending the Pavia headache centre: 51 subjects with CM and 41 with EM. Patients were tested with disability scales (MIDAS, HIT-6, SF-36) and with an ad hoc semi-structured questionnaire.ResultsThe direct mean annual cost (in euro) per patient suffering from CM was €2250.0 ± 1796.1, against €523.6 ± 825.8 per patient with EM. The cost loaded on NHS was €2110.4 ± 1756.9 for CM, €468.3 ± 801.8 for EM. The total economic load and the different sub-items were significantly different between groups (CM vs. EM p = 0.001 for each value).CM subjects had higher scores than EM for MIDAS (98.4 ± 72,3 vs 15.5 ± 17.7, p = 0.001) and for HIT-6 (66.1 ± 8.4 vs 58.7 ± 10.1, p = 0.001). The SF-36 score was 39.9 ± 14,74 for CM and 66.2 ± 18.2 for EM (p = 0.001).ConclusionsCM is a disabling condition with a huge impact on the QoL of sufferers and a significant economic impact on the NHS. The adequate management of CM, reverting it back to EM, will provide a dual benefit: on the individual and on the society.

【 授权许可】

CC BY   
© Berra et al. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.